AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6206318
Drug: Meproscillarin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meproscillarin (0.5 to 2.0 mg/day)
Trial: 12658772
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg irbesartan capsule (test)
Trial: 12658772
Drug: irbesartan tablet
RxNorm normalized name: Irbesartan Tablets
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: irbesartan tablet (reference)
Trial: 1673089
Drug: CQA 206‐291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQA 206‐291 (mixed D1‐D2 receptor agonist)
Trial: 7036712
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg cimetidine
Trial: 7036712
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg cimetidine
Trial: 31866083
Drug: HRT or
RxNorm normalized name: Femhrt Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT or oral contraception use
Trial: 22858806
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (Tacrolimus/Mycophenolate Mofetil/steroids)
Trial: 11350323
Drug: Propofol (ED50:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (ED50: 3.45 mg x kg(‐1) x h(‐1), ED95: 6.68 mg x kg(‐1) x h(‐1))
Trial: 9346217
Drug: Paclitaxel (Taxol)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (Taxol) in combination with carboplatin
Trial: 31314569
Drug: Infants receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants receiving ≤4 fl oz daily of formula in the first month
Trial: 31314569
Drug: Infants receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants receiving formula daily (not specified volume)
Trial: 31314569
Drug: Infants receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants receiving ≤4 fl oz daily of formula
Trial: 23377511
Drug: Clindamycin 1.2%‐tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 1.2%‐tretinoin 0.025% (CLIN/RA) gel
Trial: 23377511
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 2.5%‐adapalene 0.1% (BPO/ADA) gel
Trial: 19020122
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg dexamethasone (Group D1)
Trial: 19020122
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg dexamethasone (Group D2)
Trial: 12614528
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (historic control)
Trial: 10403616
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 mg once daily)
Trial: 10403616
Drug: Felodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (10 mg once daily)
Trial: 7720941
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (3.75 mg IM leuprolide acetate every 28 days for 6 months)
Trial: 7720941
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (combination monophasic for 6 months)
Trial: 7720941
Drug: Combination GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination GnRH agonist and oral contraceptive (LA + OC for 6 months)
Trial: 30796919
Drug: Specialized Physical
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized Physical Therapy (SPT)
Trial: 30796919
Drug: Regular Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Physical Therapy (RPT)
Trial: 27631821
Drug: Short-term dual
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term dual antiplatelet therapy (DAPT) (6 months or less)
Trial: 27631821
Drug: Prolonged dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged dual antiplatelet therapy (DAPT) (12 months or more)
Trial: 24760352
Drug: 3.1% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.1% sodium chloride solution (hypertonic saline)
Trial: 21537493
Drug: p-synephrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-synephrine (50 mg)
Trial: 21537493
Drug: p-synephrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-synephrine (50 mg) + naringin (600 mg)
Trial: 21537493
Drug: p-synephrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-synephrine (50 mg) + naringin (600 mg) + hesperidin (100 mg)
Trial: 21537493
Drug: p-synephrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-synephrine (50 mg) + naringin (600 mg) + hesperidin (1000 mg)
Trial: 19616143
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control group (n=42)
Trial: 17162192
Drug: Allopurinol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (40 mg/kg/day, 3 days)
Trial: 15167086
Drug: Parent-infant home-visiting
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-infant home-visiting services (0 to 18 months of weekly visits)
Trial: 8071511
Drug: Supplemental nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental nasal oxygen (2 l/min)
Trial: 2647817
Drug: Heparin (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5,000 IU in a bolus injection)
Trial: 4426706
Drug: C14‐S5 strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C14‐S5 strain with varying doses
Trial: 26061762
Drug: 10% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% maltodextrin solution (CHO)
Trial: 23863810
Drug: pioglitazone (PGZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone (PGZ; 45 mg/day)
Trial: 19519298
Drug: Gefitinib or
RxNorm normalized name: gefitinib Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib or Erlotinib in combination with chemotherapy
Trial: 9412258
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of propofol (5‐8 mg/kg.h)
Trial: 9412258
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion regimen
Trial: 7682167
Drug: Conventional enteric-coated
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional enteric-coated tablet of diclofenac sodium 50 mg orally, thrice daily
Trial: 3806153
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (thiazide diuretic and propranolol if needed)
Trial: 3806153
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal preparation (mixture of 12 herbs)
Trial: 27771274
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) administered 3 times a day for 2 consecutive days, each cycle lasting 1 to 3 hours
Trial: 27771274
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (oxygen, early mobilization, a program of breathing exercises and diuretics)
Trial: 23570299
Drug: Peroxide bleaching
RxNorm normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroxide bleaching gel Opalescence PF 20, treated 25 times for eight hours per day.
Trial: 23570299
Drug: Peroxide bleaching
RxNorm normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroxide bleaching gel Opalescence PF 20.
Trial: 22118569
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g high-MW oat β-glucan (3H, n = 67)
Trial: 22118569
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g medium-MW oat β-glucan (4M, n = 50)
Trial: 22118569
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g medium-MW oat β-glucan (3M, n = 54)
Trial: 22118569
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g low-MW oat β-glucan (4L, n = 51)
Trial: 17022023
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of infertility (physician diagnosis, prescription for infertility medication, or evaluation at infertility clinics)
Trial: 17022023
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of clomiphene citrate within 60 days before to 15 days after conception
Trial: 17022023
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prescription of clomiphene citrate)
Trial: 15163330
Drug: Nutritional programme
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional programme (12 mg/day iron and 6000 IU/week vitamin A)
Trial: 15163330
Drug: Oxandrolone therapy
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxandrolone therapy (5 mg/day for 6 months)
Trial: 15163330
Drug: Testosterone depot
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone depot (100 mg monthly for 3 months or 6 months)
Trial: 2889306
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of SMS 201-995 (50 micrograms and 100 micrograms a day)
Trial: 2889306
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of SMS 201-995 (100 micrograms)
Trial: 2889306
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of SMS 201-995
Trial: 2889306
Drug: Multiple subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple subcutaneous injections of SMS 201-995 (100 micrograms each)
Trial: 27351628
Drug: Everolimus (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (4.5 mg/m2/day, titrated to a target blood trough of 5-15 ng/mL)
Trial: 22715833
Drug: Cold air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold air application in palm injections
Trial: 20501394
Drug: BUMA drug-eluting
RxNorm normalized name: Bumadizone
DrugBank: Bumadizone (DB13286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUMA drug-eluting stent
Trial: 20129543
Drug: Endeavor drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endeavor drug-eluting stent
Trial: 3310017
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sodium hyaluronate
Trial: 30077383
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement with ultra-wide 7-mm-diameter implants
Trial: 30077383
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement in molar healed sites after socket preservation
Trial: 21492416
Drug: Azithromycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (30 mg/kg/dose) administered once weekly for three doses
Trial: 21492416
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once weekly for three doses
Trial: 15232360
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 40 mg twice daily for 7 days
Trial: 15232360
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg 4 times daily for 5 days
Trial: 8201970
Drug: Theophylline (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (IV bolus of 220 mg followed by IV infusion of 1 mg/kg/h)
Trial: 3354399
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (230 patients)
Trial: 3354399
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (218 patients)
Trial: 21199268
Drug: Glimepiride (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (starting dose 1 mg/day, max 6 mg/day)
Trial: 16713501
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration study with feedback and information about harmful effects
Trial: 16713501
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration study
Trial: 12898439
Drug: intermittent subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent subcutaneous IL-2 and placebo
Trial: 12898439
Drug: intermittent subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent subcutaneous IL-2 and prednisone
Trial: 7602215
Drug: MDT +
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MDT + BCG (rifampin once a month, clofazimine and dapsone daily, BCG intradermally 0.1 mg/dose)
Trial: 7602215
Drug: MDT +
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MDT + Mycobacterium w (same MDT with 2 x 10(8) killed bacilli/dose i.d.)
Trial: 31864519
Drug: Individualized rehabilitation
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized rehabilitation and chiropractic treatment
Trial: 18641526
Drug: Debridement twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debridement twice a week (Group 1)
Trial: 16875473
Drug: TAC (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (10 mg/mL) injected weekly for 8 weeks
Trial: 16875473
Drug: TAC (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (40 mg/mL) + 5-FU (50 mg/mL) injected weekly for 8 weeks
Trial: 16875473
Drug: TAC (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (40 mg/mL) + 5-FU (50 mg/mL) injected weekly for 8 weeks + PDL (5-7.5 J/cm2) at 1st, 4th, and 8th weeks
Trial: 10718774
Drug: 10 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, 20 mg, and 10 + 20 mg tablets; solution administered once daily for 2 weeks
Trial: 14584871
Drug: One-stage full-mouth
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage full-mouth scaling and root planing (FMSRP) plus amoxicillin/clavulanic acid 875 mg (G1)
Trial: 11469284
Drug: Early occupational
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early occupational therapy intervention, given weekly at home from six months to 12 months.
Trial: 28126333
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy (cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2 every 3 weeks for four cycles followed by maintenance pemetrexed)
Trial: 26432173
Drug: Therapy process
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy process at the end stage
Trial: 23239676
Drug: Beta-alanine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (80 mg · kg‐1 BM · d‐1)
Trial: 18287411
Drug: Percutaneous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection (PEI) + radiofrequency ablation (n = 50)
Trial: 16541860
Drug: Oral Biyankang,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Biyankang, 4 tablets each time, 3 times daily
Trial: 18178950
Drug: Polysporin Triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysporin Triple antibiotic ointment
Trial: 8944697
Drug: Telenzepine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenzepine (selective M1-receptor antagonist)
Trial: 6758743
Drug: Labetalol (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (twice daily dosage)
Trial: 31594196
Drug: Whole-body cryotherapy
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cryotherapy at -110°C with exercise therapy
Trial: 31594196
Drug: Whole-body cryotherapy
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cryotherapy at -60°C with exercise therapy
Trial: 12875346
Drug: Current oral
RxNorm normalized name: black currant oil Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current oral suspension
Trial: 12875346
Drug: Former oral
RxNorm normalized name: Triple Wormer Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Former oral suspension
Trial: 10505695
Drug: Eicosapentanoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentanoic acid (EPA) at a dose of 1800 mg daily for 3 months
Trial: 7559196
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg bd iv)
Trial: 7559196
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (ceftazidime 1 g bd iv, ampicillin 500 mg qds iv, metronidazole 500 mg tds iv)
Trial: 31970564
Drug: PBM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM therapy with a CW GaAIAs diode laser (808 nm; 0.028 mm2; 0.1 W; 3.6 W/cm2; 89 J/cm2; 2.5 J/point)
Trial: 29021311
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment arm (n=30)
Trial: 29021311
Drug: Emergency endovascular
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency endovascular treatment of the extracranial disease (n=17)
Trial: 29021311
Drug: Antithrombotic agents
RxNorm normalized name: ANTITHROMBOTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic agents after acute carotid artery stenting
Trial: 17094088
Drug: Sarizotan 2
RxNorm normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarizotan 2 mg/day
Trial: 17094088
Drug: Sarizotan 10
RxNorm normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarizotan 10 mg/day
Trial: 17094088
Drug: Sarizotan (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarizotan (2, 4, or 10 mg/day)
Trial: 15733882
Drug: 1-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g oral dose of secnidazole (n=44)
Trial: 15733882
Drug: 2-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g oral dose of secnidazole (n=32)
Trial: 15733882
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of secnidazole
Trial: 11315503
Drug: Red palm
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red palm oil (90 mg beta-carotene)
Trial: 11315503
Drug: Beta-carotene supplements
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplements
Trial: 9252738
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate emollient 0.05 percent, 0.43 to 0.5 gm twice daily for four weeks
Trial: 9252738
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate emollient, 1.5 gm applied twice daily for seven consecutive days
Trial: 30220621
Drug: Laser groove
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser groove treatment (100μm-deep, 150μm-deep, 200μm-deep)
Trial: 30220621
Drug: Air abrasion
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air abrasion treatment
Trial: 28150850
Drug: Chewing 180
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing 180 mg ticagrelor